Vorasidenib, an inhibitor of both mutant IDH1 and IDH2, was tested in a double-blind Phase 3 trial which included 331 patients with residual or recurrent grade 2 IDH-mutant glioma (Mellinghoff et al., 2023). Here, IDH1 is linked to glioma.